Abstract
Overview
Introduction
Today, pharma companies face growing competition from generics and me-too
drugs, combined with increasingly tough P&R, a clamp down on healthcare
spending, and the need to treat patients for longer due to the aging
population. These factors threaten both current and future revenues prompting
Pharma to adopt a range of corporate strategies to respond to the changing
market dynamics.
Scope
- Review of key external factors impacting Pharma and shaping their
strategies
- Analysis of steps undertaken by pharma companies to achieve cost saving
and improve efficiency
- Assessment of corporate strategies employed by drug developers to generate
new revenue growth
Report Highlights
Fewer drugs are gaining FDA approval year-on-year, primarily due to increasing
pressure the pharmaceutical industry is facing over drug safety, fueled by
several recent high-profile drug withdrawals and black box warnings.
Compounded with the recent expansion of the FDA' s safety powers, this will
have a negative impact on Pharma' s profitability.
The pharmaceutical industry is facing increasingly cost-conscious times, with
a declining ROI and numerous blockbuster products facing imminent generic
competition. This is exacerbated by the increasing cost of licensing and M&A
deals, and a harshening P&R environment.
A key trend in 2007 has been the vast number of job cuts across Big Pharma in
an effort to cut costs, in response to disappointing financial results driven
by patent expiries of key products and resulting generic erosion. Price
pressure and low reimbursement rates, which are impacting company revenues,
are set to continue in 2008.
Reasons to Purchase
- Identify the key trends that are impacting the industry in 2007, going
forward in 2008 and beyond
- Understand what strategic steps pharma companies are making to maintain
their profitability by cutting costs
- Gain insight into how Pharma are capturing new opportunities to sustain
historic growth rates
| 
View Cart
